BLA 203314 · Novo
Tresiba
Insulin Degludec · Subcutaneous · Insulin Analog
NovelLast checked: Nov 20, 2026Latest source record: Jul 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Sep 25, 2015
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
212
87 Phase 3, 8 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Degludec" as an intervention, any sponsor and status, largest first.
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular EventsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01959529 · 7,637 participants · Start Oct 29, 2013 · Primary completion Oct 16, 2016
Drug: insulin degludec; insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Montgomery, Alabama; Gilbert, Arizona · 446 sites in all
- Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01336023 · 1,663 participants · Start May 23, 2011 · Primary completion May 24, 2012
Drug: insulin degludec/liraglutide; insulin degludec and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Anaheim, California; Bermuda Dunes, California · 302 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03078478 · 1,609 participants · Start Mar 13, 2017 · Primary completion Feb 13, 2019
Drug: Insulin degludec; Insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Anniston, Alabama; Birmingham, Alabama; Chandler, Arizona · 229 sites in all
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03882970 · 1,444 participants · Start Apr 1, 2019 · Primary completion Dec 11, 2020
Drug: Tirzepatide; Insulin Degludec · For: Type 2 Diabetes Mellitus
Sites: Little Rock, Arkansas; Fresno, California; Huntington Park, California · 122 sites in all
- A Study of LY900014 in Participants With Type 1 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03214367 · 1,392 participants · Start Jul 17, 2017 · Primary completion Sep 6, 2018
Drug: LY900014; Insulin Lispro and 2 more · For: Type 1 Diabetes Mellitus
Sites: Mobile, Alabama; Concord, California; Escondido, California · 172 sites in all
- Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03268005 · 1,264 participants · Start Sep 19, 2017 · Primary completion Jan 7, 2019
Drug: Faster-acting insulin aspart; Insulin aspart and 2 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Concord, California; Fresno, California; Fullerton, California · 167 sites in all
- Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02500706 · 1,108 participants · Start May 4, 2016 · Primary completion Jul 17, 2017
Drug: Faster-acting insulin aspart; insulin aspart and 1 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Tucson, Arizona; Concord, California; Encino, California · 152 sites in all
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04760626 · 1,085 participants · Start Mar 1, 2021 · Primary completion Aug 12, 2022
Drug: Insulin icodec; Insulin Glargine 100U/mL and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Guntersville, Alabama; Gilbert, Arizona · 311 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tresiba (Insulin Degludec)
2024 spending
$33.5M
Beneficiaries
15,624
51,551 claims
Per beneficiary
$2,144
$32.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,045,868 |
| 2021 | $22,585,102 |
| 2022 | $25,802,904 |
| 2023 | $27,706,471 |
| 2024 | $33,499,311 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I, Asong M, Desouza C, et al. · JAMA 2023 · Clinical Trial, Phase III, Equivalence Trial
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A, Cusi K, Fernández Landó L, et al. · Lancet Diabetes Endocrinol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials.
Thammakosol K, Vongtangton P, Numthavaj P, et al. · Diabetes Obes Metab 2026 · Systematic Review, Meta-Analysis
- Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.
Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. · Lancet Diabetes Endocrinol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M, Sadeghi M, Barzkar F, et al. · Front Endocrinol (Lausanne) 2024 · Systematic Review, Network Meta-Analysis
- Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A, Asong M, Franek E, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Novo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.